At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 73 enrolled
Drug / intervention
Dexamethasone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Double-Masked, Vehicle Controlled Phase 3 Study Evaluating the Efficacy and Safety of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (CAC®)
In Brief
A Phase 3 clinical trial evaluating Dexamethasone and Placebo Vehicle for Chronic Allergic Conjunctivitis. Completed, enrolled 73 participants.
Detailed Summary
The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of chronic allergic conjunctivitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Allergic Conjunctivitis
Countries--
CollaboratorsORA, Inc.
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartApr 2015
First PostedMay 2015
Primary CompletionAug 2015
Study CompletionSep 2015
TodayJul 2026
First PostedMay 15, 2015
Enrollment StartApr 1, 2015
Primary CompletionAug 1, 2015
Study CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 11.1 years ago
Interventions
Dexamethasonedrug
Placebo Vehicleother